Larimar Therapeutics (LRMR) vs Scribe Therapeutics (SCTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Scribe Therapeutics is the larger company by market cap ($369.4 million vs $275.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LRMR | SCTX |
|---|---|---|
| Share price | $2.65 | $19.51 |
| Market cap | $275.29M | $369.36M |
| 1-day change | -1.85% | +1.46% |
| YTD return | -29.13% | — |
| 1-year return | -43.98% | — |
| 5-year return | -77.72% | — |
| EPS (TTM) | $-1.99 | $-3.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.42 | $39.60 |
| 52-week low | $2.61 | $13.50 |
| Distance from 52-week high | -58.72% | -50.73% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +443.40% | +192.16% |
| Average volume | 1.27M | 357.40K |
| Shares outstanding | 103.88M | 18.93M |
| Employees | 71 | 82 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
About Scribe Therapeutics
SCTX stock →Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees
LRMR vs SCTX FAQ
Which is bigger, Larimar Therapeutics or Scribe Therapeutics?
Scribe Therapeutics (SCTX) is larger, with a market capitalization of $369.36M compared with $275.29M for Larimar Therapeutics (LRMR).
Are Larimar Therapeutics and Scribe Therapeutics in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Larimar Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Scribe Therapeutics.